Drug Trial Radar · NCT03601078
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
Dec 13, 2018
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), in participants with multiple myeloma (MM) having progressed within 18 months of initial treatment with autologous stem cell transplantation (ASCT) (Cohort 2a) and without ASCT (Cohort 2b) or, in participants with inadequate response post ASCT during initial treatment (Cohort 2c) and the efficacy and safety of bb2121 used in combination with lenalidomide maintenance in participants with suboptimal response post ASCT (Cohort 3). Approximately 248 participants will be enrolled into one of three cohorts. Cohort 1 (including cohort 1b) will enroll approximately 126 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed multiple myeloma (NDMM) participants with suboptimal response to ASCT.
Conditions
- Multiple Myeloma
Interventions
bb2121Biological
bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
LenalomideDrug
Specified dose on specified days
TalquetamabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)- Cohort 1Time frame: Up to approximately 5 years (Participants will transition to the long term follow-up (LTFU) study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)
- Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3Time frame: Up to approximately 5 years (Participants will transition to the LTFU study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)
Locations
25 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Scottsdale
Scottsdale, Arizona
University Of California San Francisco Medical Center
San Francisco, California
Moffitt Cancer Center
Tampa, Florida
Emory University School of Medicine
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Washington University
St Louis, Missouri
University Of Nebraska
Omaha, Nebraska
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Mt Sinai Medical Center - NY
New York, New York
Columbia University Medical Center/New York-Presbyterian Hospital
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Tennessee Oncology PLLC
Nashville, Tennessee
University Of Texas Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center The University of Texas
Houston, Texas
Swedish Cancer Inst
Seattle, Washington
Froedtert Hospital BMT Medical College of Wisconsin
Milwaukee, Wisconsin
Local Institution - 404
Poitiers, France
Local Institution - 506
Hamburg, Germany
Local Institution - 505
Würzburg, Germany
Local Institution - 603
Bologna, Italy
Clinica Universidad de Navarra
Pamplona, Spain
Local Institution - 704
Salamanca, Spain
Kings College Hospital NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.